Serum lipids and cardiac function correlate with nitrotyrosine and MMP activity in coronary artery disease patients

European Journal of Clinical Investigation

Volumn 45, Issue 7, 2015, Pages 692-701

  Bencsik, Péter ^a,b   Sasi, Viktor ^c   Kiss, Krisztina ^a   Kupai, Krisztina ^a   Kolossváry, Márton ^d   Maurovich Horvat, Pál ^d   Csont, Tamás ^c   Ungi, Imre ^c   Merkely, Béla ^d   Ferdinandy, Péter ^b,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b PHARMAHUNGARY GROUP   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cardiac function; Coronary artery disease; Lipids; Matrix metalloproteinase; Nitro oxidative stress; Nitrotyrosine

Indexed keywords

3 NITROTYROSINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; NITRIC ACID DERIVATIVE; NITROGEN; PEROXYNITRITE; TRIACYLGLYCEROL; UREA; 3-NITROTYROSINE; BIOLOGICAL MARKER; TYROSINE;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; HEART; LIPID METABOLISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PILOT STUDY;

AGED; BIOMARKERS; CORONARY ARTERY DISEASE; FEMALE; HEART; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NITROGEN; PILOT PROJECTS; TYROSINE; UREA;

EID: 84933278666     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12458     Document Type: Article

References (42)

1. Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-64.
2. Dorman G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2007;2:186-94.
3. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-42.
4. Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 2012;98:31-6.
5. Ali MA, Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosci 2009;14:699-716.
6. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-342.
7. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007;6:662-80.
8. Bencsik P, Kupai K, Giricz Z, Gorbe A, Huliak I, Furst S et al. Cardiac capsaicin-sensitive sensory nerves regulate myocardial relaxation via S-nitrosylation of SERCA: role of peroxynitrite. Br J Pharmacol 2008;153:488-96.
9. Ferdinandy P. Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol 2006;148:1-3.
10. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-80.
11. Nguyen VH, McLaughlin MA. Coronary artery disease in women: a review of emerging cardiovascular risk factors. Mt Sinai J Med 2002;69:338-49.
12. Warnholtz A, Mollnau H, Oelze M, Wendt M, Munzel T. Antioxidants and endothelial dysfunction in hyperlipidemia. Curr Hypertens Rep 2001;3:53-60.
13. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-58.
14. Ungi I, Ungi T, Ruzsa Z, Nagy E, Zimmermann Z, Csont T et al. Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplasty. Chest 2005;128:1623-8.
15. Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T et al. Matrix metalloproteinase activity assays: importance of zymography. J Pharmacol Toxicol Methods 2010;61:205-9.
16. Radak Z, Ogonovszky H, Dubecz J, Pavlik G, Sasvari M, Pucsok J et al. Super-marathon race increases serum and urinary nitrotyrosine and carbonyl levels. Eur J Clin Invest 2003;33:726-30.
17. Csont T, Csonka C, Onody A, Gorbe A, Dux L, Schulz R et al. Nitrate tolerance does not increase production of peroxynitrite in the heart. Am J Physiol Heart Circ Physiol 2002;283:H69-76.
18. Campos CM, van KD, Farooq V, Simonton CA, Kappetein AP, Sabik JF III et al. Long-term forecasting and comparison of mortality in the evaluation of the xience everolimus eluting stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. Eur Heart J 2015;In press.
19. Yotti R, Bermejo J, Benito Y, Antoranz JC, Desco MM, Rodriguez-Perez D et al. Noninvasive estimation of the rate of relaxation by the analysis of intraventricular pressure gradients. Circ Cardiovasc Imaging 2011;4:94-104.
20. Sigala F, Kotsinas A, Savari P, Filis K, Markantonis S, Iliodromitis EK et al. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg 2010;52:704-13.
21. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003;57:426-33.
22. Polewicz D, Cadete VJ, Doroszko A, Hunter BE, Sawicka J, Szczesna-Cordary D et al. Ischemia induced peroxynitrite dependent modifications of cardiomyocyte MLC1 increases its degradation by MMP-2 leading to contractile dysfunction. J Cell Mol Med 2011;15:1136-47.
23. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007;43:429-36.
24. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165-74.
25. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010;31:2741-8.
26. Onody A, Csonka C, Giricz Z, Ferdinandy P. Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. Cardiovasc Res 2003;58:663-70.
27. Csont T, Bereczki E, Bencsik P, Fodor G, Gorbe A, Zvara A et al. Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. Cardiovasc Res 2007;76:100-9.
28. Pirro M, Schillaci G, Mannarino MR, Savarese G, Vaudo G, Siepi D et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2007;17:436-41.
29. Esposito K, Ciotola M, Schisano B, Misso L, Giannetti G, Ceriello A et al. Oxidative stress in the metabolic syndrome. J Endocrinol Invest 2006;29:791-5.
30. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009;40:48-53.
31. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22:361-70.
32. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001;39:380-4.
33. Nilsson L, Eriksson P, Cherfan P, Jonasson L. Effects of simvastatin on proinflammatory cytokines and matrix metalloproteinases in hypercholesterolemic individuals. Inflammation 2011;34:225-30.
34. Nakaya R, Uzui H, Shimizu H, Nakano A, Mitsuke Y, Yamazaki T et al. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005;105:67-73.
35. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006;12:514-9.
36. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y et al. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci 2007;112:43-9.
37. Wang TD, Lee CM, Wu CC, Lee TM, Chen WJ, Chen MF et al. The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis 1999;146:117-24.
38. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis 2004;15:251-8.
39. Fujiwara T, Saito S, Osanai T, Kameda K, Abe N, Higuma T et al. Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin. Eur J Pharmacol 2008;594:146-51.
40. Koh KK, Son JW, Ahn JY, Choi YM, Jin DK, Park GS et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis 2001;12:305-11.
41. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
42. Vaitkus PT. Current status of prevention, diagnosis, and management of coronary artery disease in patients with kidney failure. Am Heart J 2000;139:1000-8.